• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

ViaCyte Inc.

ViaCyte launches cell replacement trial for Type I diabetes

August 1, 2017 By Sarah Faulkner

Regenerative medicine company ViaCyte said today that the first patients have been implanted in a trial of its islet cell replacement therapy, PEC-Direct. San Diego-based ViaCyte is developing the cell therapy as a functional cure for patients with Type I diabetes who are at risk of suffering acute life-threatening complications. Get the full story at our sister […]

Filed Under: Clinical Trials, Diabetes, Pharmaceutical, Stem Cells, Wall Street Beat Tagged With: Juvenile Diabetes Research Foundation (JDRF), ViaCyte Inc.

ViaCyte looks to cell replacement therapy to cure Type I diabetes

May 22, 2017 By Sarah Faulkner

ViaCyte said today that it will begin clinical trials of its novel islet cell replacement therapy in development as a potential cure for Type I diabetes, after landing regulatory wins from the FDA and Health Canada. The company’s PEC-Direct candidate delivers stem cell-derived pancreatic progenitor cells in a device that is designed to enable direct […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Food & Drug Administration (FDA), Funding Roundup, Wall Street Beat Tagged With: Juvenile Diabetes Research Foundation (JDRF), ViaCyte Inc., W.L. Gore & Associates

ViaCyte ropes in $10.6M for artificial pancreas

July 11, 2013 By Sony Salzman Leave a Comment

ViaCyte ropes in $10.6M for artificial pancreas

Filed Under: Funding Roundup, News Well Tagged With: California Institute for Regenerative Medicine, Johnson and Johnson, Johnson Trust, Sanderling Ventures, ViaCyte Inc.

Stryker hits a 52-week high | Wall Street Beat

February 14, 2013 By MassDevice staff Leave a Comment

MassDevice.com Wall Street Beat

Shares of Stryker (NYSE:SYK) hit a 52-week high yesterday, peaking at $64.46 apeice before closing at $63.88, down 0.2% on the day.

STK shares are up about 3% since the medical device company reported 4th-quarter and 2012 results Jan. 24. Stryker said yesteday that it plans to issue a 26.5¢ dividend to shareholders.

Filed Under: Funding Roundup, MassDevice Earnings Roundup, Neuromodulation/Neurostimulation, News Well, Regenerative Medicine, Stem Cells, Wall Street Beat, Weight loss Tagged With: 2012, Boston Scientific, California Institute for Regenerative Medicine, Dialysis, Direct-to-Consumer, EnteroMedics Inc., Juvenile Diabetes Research Foundation, Q4, Stryker, ViaCyte Inc.

Practice Fusion announces first VP of product management | Personnel Moves

June 16, 2011 By MassDevice staff Leave a Comment

MassDevice.com Personnel Moves

Here’s the latest personnel changes from medical device, diagnostics and life science companies around the nation. For more recent hirings and firings, check out MassDevice’s compilation of the latest personnel moves.

Filed Under: Business/Financial News, News Well Tagged With: Allegro Diagnostics, Cleveland Clinic, Freeland Systems, Generex Biotechnology Corp., HeartSine Technologies Inc., Hotspur Technologies Inc., Personnel Moves, Practice Fusion, RepRegen, Summa Cardiovascular Institute, ViaCyte Inc.

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy